Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review

Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review

Inflammatory bowel diseases (IBDs) are complex immune-mediated disorders characterised by an unpredictable direction and commonly associated metabolic comorbidities along with obesity and type 2 diabetes mellitus (T2DM). Recent evidence has highlighted the therapeutic capacity of glucagon-like pepti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Antonietta Gerarda Gravina, Raffaele Pellegrino, Michele Izzo, Ilaria De Costanzo, Giuseppe Imperio, Fabio Landa, Assunta Tambaro, Alessandro Federico
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Current Issues in Molecular Biology
Subjects:	GLP-1 inflammatory bowel disease type 2 diabetes mellitus obesity diabetes gut inflammation
Online Access:	https://www.mdpi.com/1467-3045/47/5/383
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence
by: Raffaele Pellegrino, et al.
Published: (2025-02-01)

Agonistas Glucagon Like Peptide - 1 (GLP-1) y retraso del vaciamiento gástrico: Consideraciones anestésicas y clínicas
by: Gonzalo Irizaga Dávila, et al.
Published: (2024-01-01)

Clear Cell Renal Carcinoma in an Ulcerative Colitis Patient Under Short-Term Immunosuppressive Therapy: A Case Report
by: Raffaele Pellegrino, et al.
Published: (2025-04-01)

Conversational LLM Chatbot ChatGPT-4 for Colonoscopy Boston Bowel Preparation Scoring: An Artificial Intelligence-to-Head Concordance Analysis
by: Raffaele Pellegrino, et al.
Published: (2024-11-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Assessing GLP-1 RAs in Diabetic Gastroparesis: A Literature Review
by: Jacob Itkin, et al.
Published: (2025-06-01)

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
by: Duc Tin Tran, et al.
Published: (2024-11-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
by: Velimir Altabas, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
by: Sean Wharton, et al.
Published: (2025-06-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024-11-01)

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
by: Mohammed Ali Gameil, et al.
Published: (2024-12-01)

Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01)

The commercial availability of plant-based phytochemical components used in GLP-1 inhibition for the treatment of type-2 diabetes
by: Sharanjeet Kour, et al.
Published: (2025-08-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson’s disease with diabetes co-morbidity
by: Xiaomin Zhang, et al.
Published: (2025-06-01)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
by: Georgia Doumani, et al.
Published: (2024-11-01)

Too Many Couch Potatoes Among Middle-Aged Inflammatory Bowel Disease Patients: Findings from the “BE-FIT-IBD-2” Study
by: Antonietta Gerarda Gravina, et al.
Published: (2024-11-01)

Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails
by: Asmita Gera, et al.
Published: (2025-04-01)

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
by: Christoffer Clemmensen, et al.
Published: (2015-02-01)

Advances in GLP-1 receptor agonists for pain treatment and their future potential
by: Yongtao He, et al.
Published: (2025-02-01)

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
by: Maria S Varughese, et al.
Published: (2025-03-01)

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses
by: Hsuan-Wen Lai, et al.
Published: (2025-03-01)

Los agonistas del receptor GLP-1 como tratamiento en pacientes con Diabetes Mellitus Tipo II y obesidad
by: Mishelle Alexandra Quinga Amán, et al.
Published: (2025-04-01)

GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism
by: Linjie Peng, et al.
Published: (2025-03-01)

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
by: Vijay Kumar
Published: (2025-07-01)

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression
by: Amr Ahmed, et al.
Published: (2024-07-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review
by: Łukasz Karaban, et al.
Published: (2025-05-01)

GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy
by: Arif Albulushi, et al.
Published: (2025-07-01)

Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells
by: Affiong Ika Oqua, et al.
Published: (2025-04-01)